Professional
Added to YB: 2024-04-26
Pitch date: 2024-03-31
RGEN [bullish]
Repligen Corporation
-13.19%
current return
Author Info
No bio for this author
Company Info
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Market Cap
$8.6B
Pitch Price
$184.98
Price Target
N/A
Dividend
N/A
EV/EBITDA
51.33
P/E
6.0K
EV/Sales
12.03
Sector
Life Sciences Tools and Services
Category
growth
Baron Health Care Fund Added On Position: Repligen Corporation
RGEN: Bioprocessing tools for monoclonal antibodies (10-12% market growth) & cell/gene therapies (25%+). Differentiated filters & real-time monitoring drive adoption in sticky workflows. Growth held back by destocking & China issues but turning a corner. Attractive long-term prospects.
Read full article (1 min)